Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis
Authors
Keywords
-
Journal
ESMO Open
Volume 7, Issue 6, Pages 100591
Publisher
Elsevier BV
Online
2022-10-06
DOI
10.1016/j.esmoop.2022.100591
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- T cells: Friends and foes in NASH pathogenesis and hepatocarcinogenesis
- (2022) Pierluigi Ramadori et al. HEPATOLOGY
- Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
- (2022) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma
- (2022) Ambreen Muhammed et al. Cancers
- VALIDATION OF THE EASY‐TO‐USE LENVATINIB PROGNOSTIC (LEP) INDEX TO PREDICT PROGNOSIS IN ADVANCED HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH LENVATINIB.
- (2022) Margherita Rimini et al. HEPATOLOGY RESEARCH
- Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial
- (2022) Robin Kate Kelley et al. LANCET ONCOLOGY
- Hepatocellular carcinoma
- (2021) Josep M. Llovet et al. Nature Reviews Disease Primers
- Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis
- (2021) Andrea Casadei‐Gardini et al. LIVER INTERNATIONAL
- Molecular characterization of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis
- (2021) Roser Pinyol et al. JOURNAL OF HEPATOLOGY
- Non-alcoholic fatty liver disease
- (2021) Elizabeth E Powell et al. LANCET
- NASH limits anti-tumour surveillance in immunotherapy-treated HCC
- (2021) Dominik Pfister et al. NATURE
- Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma
- (2021) I.G. Rapposelli et al. ESMO Open
- Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study
- (2021) Margherita Rimini et al. HEPATOLOGY RESEARCH
- Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
- (2021) Thomas Yau et al. LANCET ONCOLOGY
- Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy
- (2021) Valentina Burgio et al. Cancer Management and Research
- Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer
- (2021) Caroline A. Nebhan et al. JAMA Oncology
- Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib
- (2021) M. Rimini et al. ESMO Open
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti–PD‐1 therapy
- (2020) Sirish Dharmapuri et al. Cancer Medicine
- O-8 Atezolizumab + bevacizumab vs sorafenib for unresectable hepatocellular carcinoma: Results from older adults enrolled in IMbrave150
- (2020) D. Li et al. ANNALS OF ONCOLOGY
- Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
- (2020) Saur Hajiev et al. BRITISH JOURNAL OF CANCER
- Systemic treatment of HCC in special populations
- (2020) Lorenza Rimassa et al. JOURNAL OF HEPATOLOGY
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis
- (2019) Vincenzo Di Nunno et al. Immunotherapy
- Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer
- (2019) Mohsen Malehmir et al. NATURE MEDICINE
- From NASH to HCC: current concepts and future challenges
- (2019) Quentin M. Anstee et al. Nature Reviews Gastroenterology & Hepatology
- Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers
- (2019) Mingjia Li et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: A multicenter analysis with propensity score matching
- (2019) Toshifumi Tada et al. HEPATOLOGY RESEARCH
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- B2-Lymphocyte responses to oxidative stress-derived antigens contribute to the evolution of nonalcoholic fatty liver disease (NAFLD)
- (2018) Stefania Bruzzì et al. FREE RADICAL BIOLOGY AND MEDICINE
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- The immunology of hepatocellular carcinoma
- (2018) Marc Ringelhan et al. NATURE IMMUNOLOGY
- Mechanisms of NAFLD development and therapeutic strategies
- (2018) Scott L. Friedman et al. NATURE MEDICINE
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
- (2018) Mariaelena Capone et al. Journal for ImmunoTherapy of Cancer
- Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model
- (2018) Takayuki Kimura et al. CANCER SCIENCE
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Prognostic role of neutrophil–lymphocyte ratio in nasopharyngeal carcinoma: A meta-analysis
- (2017) Yukinori Takenaka et al. PLoS One
- Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma
- (2016) Tai Hato et al. Immunotherapy
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- (2016) JOURNAL OF HEPATOLOGY
- NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis
- (2016) Chi Ma et al. NATURE
- Effects of Ageing on the Immune System: Infants to Elderly
- (2016) R. Valiathan et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- ER Stress Cooperates with Hypernutrition to Trigger TNF-Dependent Spontaneous HCC Development
- (2014) Hayato Nakagawa et al. CANCER CELL
- Metabolic Activation of Intrahepatic CD8+ T Cells and NKT Cells Causes Nonalcoholic Steatohepatitis and Liver Cancer via Cross-Talk with Hepatocytes
- (2014) Monika Julia Wolf et al. CANCER CELL
- NAFLD, NASH and liver cancer
- (2013) Gregory A. Michelotti et al. Nature Reviews Gastroenterology & Hepatology
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now